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Abstract
Introduction Prevention of lymphocyte apoptosis by caspase
inhibition has been proposed as a novel treatment approach in
sepsis. However, it has not been clearly demonstrated that
caspase inhibitors improve survival in sepsis models when
dosed post-insult. Also, there are concerns that caspase
inhibitors might suppress the immune response. Here we
characterize VX-166, a broad caspase inhibitor, as a novel
potential treatment for sepsis.
Methods VX-166 was studied in a number of enzymatic and
cellular assays. The compound was then tested in a murine
model of endotoxic shock (lipopolysaccharide (LPS), 20 mg/kg
IV) and a 10 d rat model of polymicrobial sepsis by caecal
ligation and puncture (CLP).
Results VX-166 showed potent anti-apoptotic activity in vitro
and inhibited the release of interleukin (IL)-1beta and IL-18. In
the LPS model, VX-166 administered 0, 4, 8 and 12 h post-LPS
significantly improved survival in a dose-dependent fashion (P <
0.0028). In the CLP model, VX-166 continuously administered
by mini-osmotic pump significantly improved survival when
dosed 3 h after insult, (40% to 92%, P = 0.009). When dosed
8 h post-CLP, VX-166 improved survival from 40% to 66% (P =
0.19). Mode of action studies in the CLP model confirmed that
VX-166 significantly inhibited thymic atrophy and lymphocyte
apoptosis as determined by flow cytometry (P < 0.01). VX-166
reduced plasma endotoxin levels (P < 0.05), suggesting an
improved clearance of bacteria from the bloodstream. Release
of IL-1beta in vivo or T-cell activation in vitro were moderately
affected.
Conclusions Our studies enhance the case for the use of
caspase inhibitors in sepsis. VX-166 itself has promise as a
therapy for the treatment of sepsis in man.
Introduction
Sepsis is a significant health problem and a major cause of
death in intensive care units worldwide. Approximately
750,000 people are afflicted annually in the United States
alone and, despite progress in intensive medical care, the mor-
tality rate still ranges from 30 to 60% [1]. Novel treatment
approaches, for example anti-cytokine therapies, have shown
very limited success and the only approved drug Xigris (acti-
vated protein C) shows a minor improvement in survival in a
restricted patient population [2-4]. Effective therapies are
therefore desperately needed to reduce the morbidity and
mortality associated with this disease.
Inhibition of apoptosis has recently been suggested as a novel
therapeutic approach for the prevention and treatment of sep-
sis [5,6]. Studies in septic patients and animals have demon-
strated excessive apoptosis, mainly in the intestine, lymphoid
organs and circulating lymphocytes [7-10]. This loss of
immune cells is believed to contribute to immune suppression
that is linked to disease pathogenesis and the resultantPage 1 of 11
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a day of disease onset, and patients dying from sepsis have
increased numbers of apoptotic lymphocytes in both the
peripheral circulation and the spleen [11-15]. Indeed, recent
reports suggest a causative link between the profound lym-
phocyte loss due to apoptosis and poor outcome [15,16]. The
rationale to pursue an inhibitor of apoptosis for the treatment
of sepsis is further strengthened by studies where anti-apop-
totic antibodies, small molecules or genetic approaches have
led to a survival benefit in animal models. Importantly, it was
found that prevention of lymphocyte apoptosis has a profound
positive effect on survival in sepsis models [17-20].
Caspases represent important targets for the development of
anti-apoptotic drugs. Members of the caspase family of pro-
teases are essential for both the initiation and progression of
apoptosis [21]. Caspases are upregulated in the lymphocytes
of sepsis patients and are believed to facilitate lymphocyte
death [22,23]. Both selective and broad caspase inhibitors
have been reported to improve survival in sepsis models, and
inhibition of lymphocyte apoptosis has been suggested as the
key mode of action of these compounds [20,24-27].
Despite these promising results, questions remain regarding
potential limitations of anti-apoptotic therapy in sepsis. In most
published animal studies the caspase inhibitors were dosed at
or shortly after the time of insult, thus reflecting prevention of
septicaemia rather than the treatment of sepsis itself. This,
however, does not validate caspase inhibition as a potential
therapy for patients that present with the disease.
In addition there are still concerns about how effective inhibi-
tion of caspases will be in the clinical setting. For instance,
caspase-8 has been reported to play an important role in T-cell
activation and the adaptive immune system [28]. Thus, inhibi-
tion of caspase-8 could cause T-cell anergy and add to
immune-suppression in sepsis rather than helping prevent it.
Also a subset of caspases, in particular caspase-1, plays a key
role in the activation of the pro-inflammatory cytokines IL-1β
and IL-18 [29]. The impact of a potential anti-inflammatory
component through inhibition of caspase-1 is difficult to pre-
dict in the context of sepsis. For example, elevated levels of IL-
1β and IL-18 have been linked to the pathology of sepsis and
endotoxic shock [30], and inhibition of these cytokines has
been proposed as a potential therapeutic approach. However,
anti-IL-1β therapy has proved to be ineffective in sepsis trials
[31], and inhibition of caspase-1 has been suggested as
potentially rendering individuals more susceptible to infections
and severe sepsis [32].
In this report we characterise VX-166 (Figure 1), a broad cas-
pase inhibitor with potent anti-apoptotic activity, as a novel
potential treatment for sepsis. Importantly, we demonstrate
that VX-166 improves survival in a caecal ligation and punc-
ture (CLP) model when given several hours post insult. Fur-
thermore, we alleviate some key issues regarding the immune
suppressive properties of caspase inhibitors in the context of
sepsis. Overall these data significantly strengthen the case for
caspase inhibition in this disease. They also demonstrate that
VX-166 itself represents significant progress in the develop-




Active recombinant caspase-1, -3, -4, -7 and -8 were prepared
as described previously [33,34]. Caspase-2 was purchased
from Biomol (Exeter, UK), caspase-6 from BD Biosciences
(Oxford, UK), caspase-9 from Europa Bioproducts Ltd. (Cam-
bridge, UK) and caspase-10 from Chemicon International Inc.
(Harrow, UK). Cathepsin B and granzyme B were purchased
from Merck Biosciences Ltd. (Nottingham, UK). Fluorogenic
protease substrates were purchased from Bachem Ltd. (St.
Helens, UK). All reactions were carried out at 37°C using a
Molecular Devices (Wokingham, UK) Gemini plate-reader at
460 nm (excitation wavelength of 390 nm). Caspase inhibition
Figure 1
Structure of the broad caspase inhibitor VX-166.Page 2 of 11
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described by Margolin and colleagues [34]. Irreversible kinet-
ics were analysed by calculations of second-order inactivation
rate constants (k) using GraphPad (La Jolla, CA, USA) Prism
4.0 software. A larger number for an inactivation rate constant
indicates a greater degree of inactivation. To determine the
inhibitory effect on cathepsin B, 4.25 nM of the enzyme were
added to 250 μM z-RR-AMC in 10 mM 2-morpholino-
ethanesulfonic acid pH 6.0, 1 mM DTT, 1 mM EDTA and
0.03% Brij35 in the presence or absence of VX-166 and the
reaction monitored continuously over 15 minutes. Granzyme B
was assayed, with minor modifications, as described [35] by
Thornberry and colleagues. Additional counterscreening
against a panel of 83 additional enzymes, ion channels and
receptors was carried out at MDS Pharma Services (Bothell,
WA, USA).
In vitro apoptosis assays in Jurkat cells
Jurkat cells were obtained from LGC Standards (Teddington,
UK) and were grown in RPMI 1640, 10% FCS, 2 mM L-
glutamine, 100 U/ml penicillin and 0.1 mg/ml streptomycin (all
from Sigma Aldrich Ltd., Poole, UK) at 37°C in 5% CO2/95%
humidity. Receptor- or stress-mediated apoptosis (2 × 105
cells/ml) was induced by addition of either anti-Fas antibody
CH-11 (10 ng/ml, Millipore UK Ltd., Watford, UK), TNF-α (20
ng/ml, R&D Systems, Abingdon, UK) with cycloheximide (112
ng/ml, Sigma Aldrich Ltd., Poole, UK) or staurosporine (350
ng/ml, Sigma Aldrich Ltd., Poole, UK). VX-166 was diluted into
DMSO (10 mM), further diluted in media and added at a range
of concentrations. Cells were then incubated for 18 hours.
Apoptotic cells were then labelled with Cy5-conjugated
Annexin-V (BD Biosciences, Oxford, UK) and detected using
a FMAT™ 8100 Fluorimetric Microassay Technology Reader
(Applied Biosystems, Warrington, UK). For the experiments
using anti-Fas antibody, apoptosis was additionally measured
using a Cell Death Detection ELISA kit (Roche Diagnostics
Ltd., Lewes, UK) following the manufacturer's instructions.
In vitro apoptosis assay in human aorta endothelial cells
Human aorta endothelial cells (HAEC) were purchased from
Cambrex Bio Science Wokingham Ltd., (Wokingham, UK) and
cultured as recommended by the supplier. Apoptosis was
induced in 5 × 104 cells/ml by addition of medium deprived of
serum and growth factors. VX-166 was added at a range of
concentrations as described above and the cells incubated for
48 hours at 37°C in an atmosphere of 5% CO2/95% humidity.
Apoptosis was measured using a Cell Death Detection ELISA
kit (Roche Diagnostics Ltd., Lewes, UK) following the manu-
facturer's instructions.
In vitro IL-1β and IL-18 release assay from peripheral 
blood mononuclear cells
Peripheral blood mononuclear cells (PBMC) from healthy
donors were isolated by Ficoll-Paque gradient centrifugation
from buffy coats obtained from the National Blood Transfusion
Service (Bristol, UK). For IL-1β release, 5 × 105 cells/ml were
then stimulated with 50 ng/ml lipopolysaccharide (LPS) from
Escherichia coli (Sigma-Aldrich Ltd., Poole, UK) in the pres-
ence or absence of VX-166 and incubated for 18 hours.
Secretion of IL-1β into the supernatant was determined by
ELISA (R&D Systems, Abingdon, UK) following the manufac-
turer's instructions. For IL-18 release, 7.5 × 105 cells/ml were
stimulated with 6.25 × 10-4% (w/v) Staphylococcus aureus
cell suspension (SAC; Sigma-Aldrich Ltd., Poole, UK) in the
presence or absence of VX-166 and incubated overnight. The
IL-18 content in the supernatants was quantified by ELISA
(Caltag-MedSystems Ltd., Buckingham, UK) following the
manufacturer's instructions. In both assays PBMC viability was
assessed after the 18 hours incubation time using MTS assay
(Promega UK Ltd., Southampton, UK) to ensure that the
reduction in cytokine release was not caused by a cytotoxic
effect of the compound.
In vitro IL-2 release assay from peripheral blood 
mononuclear cells
PBMC from healthy donors were isolated as described above.
To the wells of a 96-well plate previously coated with 1.5 μg/
ml anti-hCD3 (Serotec, Kidlington, UK), 5 × 105 cells/ml and
1 μg/ml anti-hCD28 (BD Biosciences, Oxford, UK) were
added. Plates were then incubated for 24 hours in the pres-
ence or absence of VX-166 or the calcineurin inhibitor FK506
(Merck Biosciences Ltd., Nottingham, UK). IL-2 release into
the supernatant was subsequently determined by ELISA (R&D
Systems, Abingdon, UK) following the manufacturer's
instructions.
Endotoxic shock in the mouse
Endotoxic shock studies were approved by the Vertex Pharma-
ceuticals Institutional Animal Care and Use Committee. Adult
male CD-1 mice (weighing 30 to 32 g; Charles River Labora-
tories, Wilmington, MA, USA) were administered LPS (from E.
coli serotype 0111:B4, Sigma-Aldrich, St. Louis, MO, USA) at
20 mg/kg iv and survival was monitored for 96 hours (n = 28
per group). VX-166 or vehicle (10% propylene glycol: 90%
sodium phosphate buffer pH 8) were administered by repeat
iv bolus at 0 hours (co-injection with LPS), 4, 8 and 12 hours
post-LPS. VX-166 was administered at 1, 3, 10 or 30 mg/kg.
Caecal ligation and puncture in the rat
CLP studies were performed in accordance with the National
Institutes of Health guidelines for the use of experimental ani-
mals and were approved by the Institutional Animal Care and
Use Committee of the Feinstein Institute for Medical
Research. Adult male Sprague-Dawley rats (weighing 275 to
325 g, Charles River Laboratories, Wilmington, MA, USA)
were fasted overnight then anaesthetised with isoflurane. The
caecum was exposed via a 2 cm midline incision. It was ligated
just distal to the ileocaecal valve, then punctured twice with an
18-gauge needle and gently squeezed to release a small
amount of faecal material to ensure patency of the perforationPage 3 of 11
(page number not for citation purposes)
Critical Care    Vol 13 No 5    Weber et al.sites before the abdominal incision was closed. Sham-oper-
ated rats underwent the same procedure with the exception
that the caecum was neither ligated nor punctured. Animals
received subcutaneous fluids (30 ml/kg saline) immediately
after the procedure. No antibiotics were administered. In the 7
and 10 day survival studies animals were re-anaesthetised 20
hours after CLP, the perforated caecum was removed and the
abdominal cavity washed twice with 40 ml of warm, sterilised
saline. The abdominal cavity was closed, anaesthetics with-
drawn and rats returned to their cages where they were
allowed free access to food and water. In the 20 hour endpoint
study the caecum was not removed. In this study blood sam-
ples were collected by cardiac puncture under terminal anaes-
thesia into heparinised syringes for the subsequent
measurement of IL-1β and bacterial endotoxin, while the thy-
mus was removed for analysis of thymocyte apoptosis.
Alzet® mini-osmotic pumps (Durect Corporation, Cupertino,
CA, USA) were used for continuous delivery of VX-166 or
vehicle (25% dimethyl sulphoxide: 75% propylene glycol).
Pumps with a 2 ml reservoir capacity and a 10 μl//h delivery
rate were used in all studies. These pumps are designed to
deliver for seven days and so would have expired two to three
days before the end of the 10 day survival studies. The mini-
osmotic pumps were filled with VX-166 (5 to 25 mg/ml or vehi-
cle) and primed overnight at 37°C prior to subcutaneous
implantation in anaesthetised rats. The 25 mg/ml concentra-
tion of VX-166 equates to an approximate dose of 0.83 mg/
kg/h for a 300 g rat. The pumps were implanted immediately
following CLP, except in the delayed onset of treatment study
in which pumps were implanted either immediately following
CLP (0 hour) or 3 or 8 hours following CLP. Sham-operated
rats were implanted with vehicle filled mini-osmotic pumps.
Determination of blood levels of IL-1β and endotoxin in 
the rat
Blood samples were centrifuged at 1500 g for 15 minutes at
4°C, the plasma was removed and stored at -80°C until analy-
sis. Plasma IL-1β levels were determined by ELISA (R&D Sys-
tems Inc., Minneapolis, MN, USA) following the manufacturer's
instructions. Plasma endotoxin levels were determined using a
Limulus amebocyte lysate (LAL) kit (Associates of Cape Cod,
Inc., East Falmouth, MA, USA) according to the manufac-
turer's instruction. Briefly, 50 μl plasma samples were diluted
1:10 in LAL reagent solution. Endotoxin (E. coli 0113:H10,
provided by the manufacturer) was used as the standard. Both
standard and samples were heated for 15 minutes at 75°C
and were then added to a 96-well plate. Pyrochrome (50 μl)
was added to each well, mixed on a plate shaker for 30 sec-
onds, and incubated for 35 minutes at 37°C followed by the
addition of 25 μl 50% acetic acid to stop the reaction. The
optical density was determined at 405 nm using a spectropho-
tometer. The levels of endotoxin were then calculated and
expressed as EU/ml.
Determination of thymocyte apoptosis by flow cytometry
Rat PBMC were isolated from heparinised blood by Ficoll
Paque (GE Healthcare Bio-Sciences Corp., Piscataway, NJ,
USA) density gradient centrifugation and washed three times
with PBS (Invitrogen, Carlsbad, CA, USA). Thymocytes and
splenocytes were obtained by gentle grinding of organs
between frosted glass slides and passing cells through a Cel-
lector® Tissue Sieve (Bellco Glass Inc., Vineland, NJ, USA).
Red blood cells in the splenocyte suspension were lysed with
ammonium chloride potassium buffer (0.15 M NH4Cl, 10 mM
KHCO3, 0.1 mM Na2EDTA in H2O). Cells were then washed
twice in PBS, counted and reconstituted in Ca2+-rich Annexin-
V binding buffer (BD Biosciences, San Jose, CA, USA) at a
concentration of 1 × 107 cells/ml. A 100 μl sample of the cell
suspension was stained with 2.5 μl Annexin-V-FITC and 1 μl
propidium iodine (PI; BD Biosciences, San Jose, CA, USA) for
15 minutes and adjusted to a total volume of 500 μl with bind-
ing buffer. Cells were then analysed by flow cytometry with the
FACS-Calibur (BD Biosciences, San Jose, CA, USA) and per-
centages of viable (Annexin-V-/PI-), early apoptotic (Annexin-
V+/PI-), late apoptotic (Annexin-V+/PI+) and necrotic (Annexin-
V-/PI+) cells were determined.
Statistical analyses of in vivo studies
Survival data is shown as Kaplan-Meier survival curves with
statistical analysis by the log-rank test. All other data is shown
as mean ± standard error of the mean and statistical compar-
isons were by two-tailed unpaired Student's t-test or one-way
analysis of variance followed by Dunnett's t-test where appro-
priate. Differences in values were considered significant if P <
0.05.
Results
VX-166 is a potent and selective broad caspase inhibitor
We screened VX-166 against a panel of recombinant cas-
pases to confirm that the compound is a potent irreversible
broad caspase inhibitor. VX-166 caused time-dependent inhi-
bition of caspase activity with second order inactivation rate
constants (k) ranging from 6 × 103 M/s against caspase-2 to
more than 1 × 106 M/s against caspases -1 and -3 (Table 1).
To evaluate selectivity, VX-166 was counter-screened against
the serine protease granzyme B and the cysteine protease
cathepsin B. Granzyme B is a protease with similar substrate
specificity to caspases [35] while cathepsin B is strongly
inhibited by a number of commercially available caspase inhib-
itors [36,37]. VX-166 did not show any inhibitory activity
against granzyme B at 50 μM and only weak inhibition of
cathepsin B at the highest concentration tested (19% inhibi-
tion at 50 μM). VX-166 (5 μM) was tested against a panel of
83 additional enzymes, ion channels and receptors that
included 28 proteases. No significant cross-reactivity was
seen (data not shown). These data indicate that VX-166 is
highly selective for caspases.Page 4 of 11
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We performed a number of cellular assays to demonstrate that
VX-166 has the ability to inhibit apoptotic processes that are
relevant in sepsis. Programmed cell death of T-cells in sepsis
is mediated by a number of stimuli (e.g. Fas ligand, TNF-α or
steroids) and can proceed via different apoptotic pathways
[6,22]. We therefore tested VX-166 in cell assays with a vari-
ety of apoptotic stimuli using the Jurkat T-cell lymphoma line.
As shown in Table 2, VX-166 potently inhibits apoptosis in Jur-
kat cells induced by both receptor-driven (Fas, TNFR) and
stress-driven (staurosporine) caspase activation pathways.
Fas-induced apoptosis was particularly sensitive to inhibition
by VX-166 as determined by Annexin-V staining and DNA-
fragmentation.
Endothelial cell apoptosis has recently also been suggested to
occur in sepsis [38,39], potentially contributing to vascular
damage causing leakage of fluid into the extravascular space
and collapse of the microcirculation. We therefore investi-
gated the ability of VX-166 to prevent the death of human pri-
mary endothelial cells in vitro. VX-166 inhibited endothelial cell
death potently, with a 50% inhibitory concentration (IC50)
value of 310 nM (Table 2). In summary our data suggest that
VX-166 rescues human cells from apoptosis regardless of
apoptotic stimulus or cell type.
VX-166 inhibits the release of pro-inflammatory 
cytokines from human primary cells
To confirm that an inhibitor of caspases -1 and -4 inhibited the
release of IL-1β and IL-18, we tested the effect of VX-166 on
cytokine-release from endotoxin-treated PBMC. VX-166
potently inhibited the release of both IL-1β and IL-18 with IC50
values below 500 nM (Table 3). A viability assay conducted
simultaneously confirmed that this inhibition of cytokine
release was not due to a cytotoxic effect of the compound.
VX-166 significantly improves survival in a murine model 
of endotoxic shock
The attractive in vitro profile of VX-166 next led us to test the
compound in a rapid and well-established murine model of
endotoxic shock. Male CD-1 mice (n = 28 per group) were
administered LPS (20 mg/kg iv) and survival was monitored
for 96 hours. VX-166 administered by repeat iv bolus (0, 4, 8
and 12 hours post-LPS) significantly improved survival in a
dose-dependent fashion (Figure 2a; log-rank test P < 0.01).
The highest dose (30 mg/kg) more than doubled the survival
rate at 96 hours compared with vehicle control. The protective
effect of VX-166 was confirmed in a second study using the
optimal dose of 30 mg/kg. VX-166 again substantially
improved survival compared with vehicle control despite an
increase in mortality in the control group due to a different
batch of LPS used (Figure 2b; P < 0.0001). Surviving mice
from the VX-166 (30 mg/kg) treated group fully recovered
from the endotoxaemia and regained normal behaviour pat-
terns. Thus VX-166 can prevent death due to endotoxic shock
rather than merely delay it.
Table 1
Second order inactivation rate constants (k) for VX-166 against 
a panel of nine caspases (n = 4 per assay).
Recombinant caspase K (M/s) × 103
Caspase-1 >1000 a
Caspase-2 6.19 ± 0.51
Caspase-3 1171 ± 183
Caspase-4 480 ± 32
Caspase-6 77 ± 3.0
Caspase-7 526 ± 1.5
Caspase-8 194 ± 52
Caspase-9 131 ± 21
Caspase-10 49 ± 3.8
A larger number for an inactivation rate constant k indicates a greater 
degree of inactivation.
a inactivation rate was above the upper limit of the assay.
Table 2
Inhibition of apoptosis by VX-166 in a variety of cell-based assays (n = 4 per assay).
Apoptotic stimulus Cell type/readout IC50 (nM)
Anti-Fas Human Jurkat cell line/Annexin V 27 ± 9
Anti-Fas Human Jurkat cell line/DNA fragmentation 45 ± 7
TNF-α/cycloheximide Human Jurkat cell line/Annexin V 120 ± 50
Staurosporine Human Jurkat cell line/Annexin V 255 ± 155
Serum withdrawal and nutrient deprivation HAEC/DNA fragmentation 310 ± 70
IC50 = 50% inhibitory concentration; HAEC = human aorta endothelial cells.Page 5 of 11
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VX-166 was assessed in a CLP model in the rat. This particu-
lar model is one of the most relevant models of sepsis and
mimics the human diseases of ruptured appendicitis or perfo-
rated diverticulitis [40]. In two studies, VX-166 was continu-
ously administered by mini-osmotic pump implanted
immediately following CLP. Because of the higher relevance of
the model continuous infusion was chosen to reflect the
potential dosing regime in the clinic. In the first study (Figure
3a; n = 12 per group) survival was monitored for seven days.
VX-166 was of significant benefit (P < 0.05 log-rank test for
trend), increasing survival at day 7 from 25% in the control
group to 67% with VX-166 at 25 mg/ml. The efficacy of the
optimal dose of VX-166 (25 mg/ml) was confirmed in the sec-
ond study (Figure 3b, n = 16 per group) in which the observa-
tion period was extended to 10 days. Again VX-166
significantly (P < 0.01) improved survival compared with vehi-
cle control.
VX-166 significantly improves survival in the rat CLP 
model when dosed post insult
Previous reports have shown that caspase inhibitors can
improve survival in sepsis models when dosed near the time of
insult [20,24-27]. However, the effect of delaying the adminis-
tration of a caspase inhibitor in the CLP model has not been
fully explored. Therefore, we assessed the therapeutic poten-
tial of VX-166 by investigating the effect of delaying treatment
until after CLP (n = 12 per group). Previous reports have
shown that CLP rats suffer from sepsis within two to five hours
post insult [41-43]. VX-166 (25 mg/ml) was administered by
mini-osmotic pump starting 0, 3 or 8 hours after CLP. Survival
was monitored for 10 days and compared with a separate
vehicle control group for each time point. As expected, VX-
166 significantly increased survival at day 10 to 83% com-
pared with 40% in the control group (P = 0.026, Figure 4a)
when dosed simultaneously with CLP. When dosing was initi-
ated three hours after insult, VX-166 still retained its efficacy
and significantly improved survival from 40% to 92% (P =
0.009, Figure 4b). When initiation of treatment was delayed
further, eight hours post-CLP, VX-166 still improved survival
from 40% to 66%; this result did not quite reach statistical sig-
nificance (P = 0.19, Figure 4c). It should be noted that at this
time point the peripheral circulation is already severely
affected in CLP rats, potentially leading to an impairment of
compound delivery from the mini-osmotic pumps. Our results
therefore indicate that caspase inhibitors such as VX-166 may
be useful as a sepsis therapy.
VX-166 preserves lymphocytes, lowers endotoxin levels 
and dampens the proinflammatory cytokine response 
following CLP in the rat
Previous studies have suggested that inhibition of lymphocyte
apoptosis is one of the key mechanisms through which cas-
Table 3
Inhibition of cytokine release by VX-166 (n = 4 per assay).
Cytokine/cell type IC50 ± SD (nM)
IL-1β/LPS-treated human PBMC 260 ± 120
IL-18/SAC-treated human PBMC 450 ± 170
IC50 = 50% inhibitory concentration; LPS = lipopolysaccharide; 
PBMC = peripheral blood mononuclear cells; SAC = 
Staphylococcus aureus cell suspension; SD = standard deviation.
Figure 2
VX-166 significantly improves survival in an endotoxic shock model in the mouse.  Survival was monitored for 96 hours following administration of a 
lethal dose of lipopolysaccharide (LPS; 20 mg/kg iv) to male CD-1 mice (n = 28 per group). VX-166 was administered by repeat iv bolus at 0, 4, 8 
and 12 hours following LPS. (a) Dose response of VX-166 dosed at 1 (triangles), 3 (empty circles), 10 (diamonds) or 30 mg/kg (squares) vs. vehicle 
control (full circles); *P < 0.01. (b) Single dose repeat study using the optimal dose (30 mg/kg) of VX-166 (squares) vs. vehicle control (circles); *P 
< 0.001. Survival in the vehicle group was different from (a) experiment due to a different batch of LPS used.Page 6 of 11
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experimental sepsis thymocyte apoptosis is associated with
rapid thymic weight loss that can be used as a simple marker
of cell death [33,34]. In the second CLP study (Figure 3b) we
measured thymus weight from surviving rats on day 10. We
found a significantly higher weight (P < 0.01) for VX-166-
treated rats compared with control animals (Figure 5a), indi-
cating the inhibition of thymocyte death in vivo. These results
are likely to be an underestimate of the protective effect of VX-
166 on thymus weight because only those control rats still sur-
viving on day 10 were included in the analysis. The effect of
VX-166 on lymphocyte apoptosis was further investigated in a
CLP study utilising an earlier (20 hour) end point when all the
control animals were still alive. VX-166 (25 mg/ml) treated
CLP rats were compared with vehicle CLP rats and a third
group of sham-operated animals that also received vehicle
mini-osmotic pumps (n = 10 per group). The proportion of thy-
mocytes undergoing apoptosis or necrosis at 20 hours was
determined by flow cytometry. The CLP procedure induced a
significant increase in early apoptotic thymocytes in the vehi-
cle CLP group compared with sham control (Figure 5b), and a
corresponding reduction in the percentage of Annexin-V-/PI-
viable cells. VX-166 significantly (P < 0.01) reduced the per-
centage of early apoptotic thymocytes compared with the
vehicle CLP group and, as a consequence, significantly
increased the percentage of viable cells. The level of necrotic
cells remained unchanged between the different groups. Thus
inhibition of lymphocyte apoptosis appears to be one of the
mechanisms by which VX-166 increases survival following
CLP.
To investigate the effect of VX-166 on the inflammatory
response, blood samples were taken at the 20 hour time point
to measure the circulating levels of IL-1β and bacterial endo-
toxin. At 20 hours, IL-1β levels were strongly increased in the
CLP vehicle group over sham operated but VX-166 caused a
significant reduction in the level of the cytokine (P < 0.05, Fig-
ure 5c) compared with vehicle alone. However, the IL-1β lev-
els in VX-166-treated animals remained elevated compared
with sham controls. VX-166 also significantly (P < 0.05)
reduced the level of endotoxin in the blood compared with the
vehicle CLP group (Figure 5d), which may be indicative of
improved clearance mechanisms.
VX-166 does not inhibit the activation of human T-cells 
in vitro below 100 μM
Several reports in the literature have suggested that caspases
are not only involved in cytokine release and apoptosis but
also in the activation of lymphocytes. Caspase-8-deficient pri-
mary human T-lymphocytes have been reported to be defec-
tive in IL-2-production after T-cell receptor stimulation [28].
Despite the protection of rodent T-cells in the CLP model a
possibility remained that VX-166 may cause anergy in stimu-
lated human lymphocytes. We therefore tested VX-166 in an
IL-2 release assay using anti-CD3/CD28 stimulated human
PBMC together with the calcineurin inhibitor FK506 as a pos-
itive control (Figure 6). FK506 inhibited IL-2 release potently
with an IC50 value of 0.2 nM, matching values published by
others [43]. VX-166 reduced IL-2 release by only 25% at 100
μM, a concentration well above the level at with VX-166 com-
pletely inhibits cellular apoptosis. The concentration of 100
μM also far exceeds the plasma levels obtained with VX-166
in vivo (data not shown). This result suggests that VX-166 is
unlikely to affect the activation of human T-cells in vivo, which
is in line with the observed preservation of the immune
response in the CLP model.
Figure 3
VX-166 significantly improves survival following CLP in the rat.  (a) Dose response of VX-166. The compound was administered by mini-osmotic 
pump (10 μl/h for seven days) implanted subcutaneously immediately after caecal ligation and puncture (CLP) and survival was monitored over 
seven days(n = 12 per group). VX-166 was dosed at 5 (diamonds), 15 (triangles), or 25 mg/ml (squares) vs. vehicle control (circles); *P < 0.05 
logrank test for trend. (b) Single dose study using the optimal dose (25 mg/ml) of VX-166 (squares) vs. vehicle control (circles). The compound was 
administered by mini-osmotic pump (10 μl/h for seven days) implanted subcutaneously immediately after CLP and survival was monitored over 10 
days (n = 16 per group); *P < 0.01.Page 7 of 11
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Our studies with VX-166 confirm other reports that a potent
small molecule caspase inhibitor can be utilised to achieve a
significant survival benefit in animal models of endotoxic shock
and polymicrobial sepsis [20,24,44,45]. We also observe inhi-
bition of lymphocyte apoptosis in vivo in line with reports by
Hotchkiss and colleagues [20,24] and Oberholzer and col-
leagues [27]. Most importantly we demonstrate that VX-166
still improves survival when dosed to CLP rats that are already
suffering from sepsis [41,42]. This shows for the first time that
caspase inhibition is able to improve survival in septic animals
when used therapeutically. VX-166 loses some of its efficacy
when dosed eight hours post insult, a timepoint where lym-
phocyte apoptosis is already evident in this model (P. Wang,
unpublished). This may indicate that a caspase inhibitor is best
used before the onset of lymphocyte death in cases of sepsis.
Alternatively the compound delivery by mini-osmotic pump
may have been impaired due to dehydration and circulation
shutdown of the animals, preventing a better outcome.
Although we determined the impact of VX-166 on T-cells it
cannot be ruled out that the compound may have affected
other leukocytes, e.g. neutrophils. The half-life of neutrophils is
increased in sepsis due to delayed apoptosis, and increased
neutrophil apoptosis has been suggested to aid the resolution
of the inflammatory process in sepsis [46]. Further studies that
assess the effect of VX-166 on neutrophils and include periph-
eral granulocyte as well as lymphocyte counts are therefore
warranted.
One concern about the use of caspase inhibitors in sepsis,
despite positive animal data, is the risk of causing T-cell anergy
in humans. This arises from reports that caspase-8 is required
for T-cell activation because mutations in the caspase-8 gene
have been shown to cause suppression of the adaptive
immune response in humans [28]. Furthermore, caspase-8
inhibition with 50 μM of the peptidic caspase inhibitors zVAD-
FMK or IETD-FMK has been described to block IL-2 release
from activated T-cells [47]. VX-166 causes partial inhibition on
T-cell activation in vitro at 100 μM. However, this moderate
effect needs to be compared with the nanomolar IC50 values
Figure 4
VX-166 improves survival following CLP in the rat when dosed post insult.  The compound was administered by mini-osmotic pump (10 μl/h for 
seven days, 25 mg/ml) implanted subcutaneously at different times after caecal ligation and puncture (CLP) and survival was monitored over 10 
days (n = 12 per group). (a) VX-166 dosed at 0 hours (empty squares) vs. vehicle control (filled squares); *P = 0.026 (b) VX-166 dosed at three 
hours (empty triangles) vs. vehicle control (filled triangles); *P = 0.009. (c) VX-166 dosed at eight hours (empty circles) vs. vehicle control (filled 
circles).Page 8 of 11
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FMK gave an IC50 value of 230 nM in our Fas-assay (data not
shown), indicating that there is a substantial window between
the anti-apoptotic and T-cell-suppressive activity of caspase
inhibitors in general. Our data therefore alleviate some con-
cerns about the use of caspase inhibitors in sepsis patients.
VX-166 is also a potent inhibitor of inflammatory caspases,
which translates into potent inhibition of cytokine release in
vitro. When dosed in the CLP model VX-166 causes attenua-
tion of the elevated IL-1β levels 20 hours post insult, but with-
out complete suppression. This finding may be explained by a
recent report that describes caspase-1-independent release
of IL-1β from neutrophils [48]. Preliminary data using VX-166
as part of a racemic mixture indicate that the release of other
cytokines such as TNF-α, IL-6 and IL-10 may also be affected
by caspase inhibition (data not shown). VX-166 may therefore
have a general dampening effect on cytokine release; how-
ever, this requires further investigation. VX-166 also reduces
blood endotoxin levels in CLP. It is not clear whether this effect
is due to a reduction of bacterial counts as described by
Hotchkiss and colleagues [24] or an alteration of endotoxin
clearance due to improved organ function. This question will
Figure 5
VX-166 has a beneficial effect on lymphocyte loss, endotoxin and IL-1β levels in CLP.  (a) Thymocyte weight of caecal ligation and puncture (CLP) 
rats from the single dose 10 days survival study was determined in surviving animals at day 10. VX-166 was dosed at 25 mg/ml (white bar) vs. vehi-
cle control (black bar); *P < 0.01. (b) Lymphocyte apoptosis was determined 20 hours post CLP (n = 10 per group) in VX-166-treated (25 mg/ml, 
white bars) vs. vehicle treated CLP rats (black bar) and sham controls (grey bar); *P < 0.01 vs. vehicle control. (c) Plasma IL-1β levels were deter-
mined 20 hours post CLP (n = 10 per group) in VX-166-treated (25 mg/ml, white bars) vs. vehicle treated CLP rats (black bar) and sham controls 
(grey bar); *P < 0.05 vs. vehicle control. (d) Plasma endotoxin levels were determined 20 hours post CLP (n = 10 per group) in VX-166-treated (25 
mg/ml, white bars) vs. vehicle treated CLP rats (black bar) and sham controls (grey bar); *P < 0.05 vs. vehicle control.
Figure 6
VX-166 does not inhibit the activation of human T-cells at concentra-tions below 100 μM
tions below 100 μM.  VX-166 and the calcineurin-inhibitor FK506 were 
tested in an IL-2 assay using anti-CD28/anti-CD3 stimulated human 
peripheral blood mononuclear cells. The compounds were added 
directly after stimulation and incubated for 24 hours. IL-2 secretion into 
the supernatant was determined by ELISA. FK506 inhibited the release 
of IL-2 with a 50% inhibitory concentration (IC50) value of 0.2 nM while 
VX-166 partly inhibited the release of IL-2 by ca. 25% at 100 μM.Page 9 of 11
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is capable of dampening the release of IL-1β at concentrations
where it causes strong inhibition of apoptosis and improve-
ment in clearance of endotoxins from the blood stream. This
profile is extremely appealing as recent data using TLR4
antagonists suggest that a modulation of pro-inflammatory
cytokine release could be beneficial in sepsis [49].
Conclusions
In summary we demonstrate that VX-166 is able to rescue
septic animals from death and alleviate concerns about
potential detrimental effects of broad caspase inhibitors in the
context of sepsis. Our studies with VX-166 enhance the case
for the use of caspase inhibitors in this indication. VX-166
itself has promise as an anti-apoptotic therapy for the treat-
ment of sepsis in humans.
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